Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for CytomX Therapeutics Inc Common Stock (CTMX).
- Disclosed ownership: 6%.
- Date of event: 30 Jun 2025.
VANGUARD GROUP INC - 30 Jun 2025 SCHEDULE 13G/A Report for CytomX Therapeutics Inc Common Stock (CTMX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- CytomX Therapeutics Inc Common Stock
- Symbol
- CTMX
- Shares outstanding
- 157,643,597 shares
- Disclosed Ownership
- 9,379,794 shares
- Ownership
- 6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 29 Jul 2025, 11:22:08 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 26 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 6% ownership in CytomX Therapeutics Inc Common Stock (CTMX) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 29 Jul 2025, 11:22.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 6% | 9,379,794 | 0 | 0 | Ashley Grim | Head of Global Fund Administration |